6-Cyanomethylene-3{62 ,5{60 -17-trihydroxy-17{60 -pregnane-21-carboxylic acid-{65 -lactone and intermediates

ABSTRACT

The anti-DCA utility of 6-cyanomethylene-3 Beta ,5 Alpha ,17trihydroxy-17 Alpha -pregnane-21-carboxylic acid gamma -lactone and its preparation via the corresponding 3-acetate are disclosed.

United States Patent [191 Lenz [ Nov. I1. 1975 6-CYANOMETHYLENE-3B,Sa-l7- TRIHYDROXY-l7a-PREGNANE-21- CARBOXYLIC AClD-y-LACTONE AND INTERMEDIATES [75] Inventor: George R. Lenz, Glenview, [IL

[73] Assignee: G. D. Searle & Co., Chicago, Ill.

[22 Filed: June 13. I974 [2!] Appl. No: 478,917

[52] U.S. Cl. 260/239.57; 260/397.1; 424/241; 424/238 [5 [1 Int. Cl. C07,] 19/00 (58} Field of Search 260/2395? 397.1

[56] References Cited UNITED STATES PATENTS 3.483.233 12/196) Stuche 260/39 Primary Examiner-Ethel G. Love Attorney, Agent or Firml0hn M Brown 2 Claims, N0 Drawings 6-CYANOMETHYLENE-3,5-l7-TRlHYDROXY-l7- PREGNAN E-Zl-CARBOXYLIC AClD--LACTONE AND INTERMEDIATES This invention relates to 6-cyanomethylene-3,5,l7-

trihydroxy-l 7-pregnane-2 l -carboxylic acid -lactone, an intermediate thereto, and a process for their preparation. More particularly, this invention provides a new, useful, and unobvious steroid having the formula no N no cucn and esters thereof, preparable by procedures well- 50 known in the art and which can be generically depicted by the formula wherein M represents hydrogen, alkali metal, alkalineearth metal/2, ammonium, or lower alkyl, and R represents hydrogen or acetyl. The term alkaline-earth metal/Z" reflects the fact that when M represents a divalent metal aforesaid, the contemplated salts are more conventionally depicted thus R being defined as before. By lower alkyl is meant methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec.- butyl, tert.-butyl, pentyl, neopentyl, hexyl, isohexyl, heptyl, and like monovalent, saturated, acyclic, straight-or branched-chain, hydrocarbon groupings of the formula C,,H

wherein n represents a positive integer less than 8.

A standardized test for the capacity of a compound to reverse the renal electrolyte effects of DCA, substantially as described by C. M. Kagawa in chapter 34 of volume ll of Evaluation of Drug Activities: Pharmaeometrics", edited by D. R. Laurence and A. L. Ba charach, can be carried out as follows: A group (Group I) of 8 male Charles River rats, each weighing between and 200 gm, is adrenalectomized and maintained thereafter on sugar cubes and tap water ad libitum overnight. Each animal is thereupon subjected to these successive treatments: (a) 0.012 mg of DCA dissolved in 0.1 ml of corn oil is injected subcutaneously; (b) 2.4 mg of test compound dissolved or suspended in 0.5 ml of corn oil or other physiologically inert solvent (e.g., aqueous 0.9% sodium chloride) is administered subcutaneoulsy or intra-gastrically, (e) 2.5 ml of aqueous 0.9% sodium chloride is injected subcutaneously. Urinary sodium and potassium are measured by customary techniques on samples of urine collected during the 4 hr. immediately following treatment. Controls are provided by second and third groups of 8 each 150 200 gm rats concurrently and identically treated excepting that in Group II, 0.33 mg of spironolactone is substituted for the test compound and the solution thereof is injected subcutaneously, while in Group lll neither test compound nor spironolactone is administered. DCA produces sodium (Na) retention, loss of potassium (K), and a corresponding reduction in the mean log Na x l0/K. spironolactone serves as an index lOIK. the validity of the test, the dose of 0.33 mg having been shown [Hofmann et al., Arch. int. pharmacodyn, 165, 476 (1967)] to induce a 50% reversal of the effects of the DCA. Kagawa [Endocrinology, 74, 724 (l964)] reported a standard error of a) 0.084 per 4-rat response, determined from a large number of tests and based on 60 degrees of freedom, for the mean log Na x l0/K. measurement. From this it can be calculated that the least significant difference (P 0.05) in mean log Na x lO/K between 2 groups of 8 rats each is m 0.168. It follows that when mean log Na V4 IO/K for Group I is equal to or greater than that for Group ll, and the latter in turn exceeds the value for Group 111 by at least 0.168 log units. the reversals of the renal electrolyte effects of DCA represented thereby are significant, A compound active at the 2.4 mg dose level is retested at lower doses until the median effective dose (MED). a dose in mg sufficient to produce a 50% inhibition of the renal electrolyte effects of the DCA administered, can be calculated. The subcutaneous MED of 6-cyanomethylene- 3,5,17trihydroxy-l7-pregnane-2l-carboxylic acid lactone in the foregoing test was found to be 1.54 mg.

Those skilled in the art will recognize that observations of activity in standardized tests for particular biological effects are fundamental to the development of valuable new drugs, both veterinary and human.

6-Cyanomethy1ene-3,5,l 7-trihydroxy-1 7pregnane- 21-carboxylic acid -lactone can be prepared by contacting 3-acety1oxy-5,l 7-dihydroxy-6-oxol 7-pregnane-2l-carboxy1ic acid -1actone with diethyl cyanomethylaahosphonate in the presence of sodium hydride, using cold 1,2-dimethoxyethane as the reaction medium and contacting the 3-acetyloxy-6- cyanomethylene-5,17-dihydroxy-17-pregnane-21-carboxylic acid -1actone which eventuates with sodium methoxide in methanol.

The following example describes in detail the afore- 3 said preparation. It will be apparent to those skilled in the art that many modifications, both of materials and Of methods, may be practiced without departing from the purpose and intent of this disclosure. Temperatures hereinafter are given in degrees Centigrade and relative amounts of materials in parts by weight, except as otherwise noted.

EXAMPLE To a mixture of parts of 57% sodium hydride in mineral oil with 25 parts of 1,2-dimcthoxycthane at 0 is added, with stirring, 26 parts of dicthyl cyano= methylphosphonate. Stirring at 0 is continued for hour, whereupon 20 parts of 3-acetyloxy-5,17-dihydroxy-6- oxo-l7-pregnane-2l-carboxylic acid -lactone (US. Pat. No. 3,012,029) and 200 parts of tetrahydrofuran are consecutively added. Stirring is continued for a further 2 hours during which the reaction mixture is brought to room temperature, at which point it is poured into a solution of 20 parts of concentrated hydrochloric acid in 980 parts of distilled water. The gummy precipitate which forms is isolated by filtration and taken up in parts of hot methanol. The resultant solution is slowly diluted with 300 parts of distilled water. A white crystalline precipitate forms. This material is 3-acetyloxy-6-cyanomethylene-S,17-dihydroxyl7-pregnane-2l-carboxylic acid -lactone which, filtered off and dried in air, melts at 236-239.

17-pregnane-2 1 -carboxylic acid -1actone.

Page 1 of 5 UNITED STATES PATENT OFFICE CERTIFICATE OF CORRECTION A PATENT NO. 5 919 199 DATED November 11 1975 INVENTOR(S) George R. Lenz It is certitred that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown DBIOWL Column 1, line 2, "ACID-LACTONE" should read ACID- Y-LACTONE Column 1, line t, "3,5,1?" should read 3B,5u,l7

Column 1, line2l, "17-" should read 1701- Column 1, line 21, "lactone" should read -lactone Column 1, line 46, "3,5,17-" should read 3B,5ot,l7-

Column 1, line 46, "trihydroxy-l?" should read trihydroxy-Not UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION Page 2 r 5 PATENT NO. 3,919,199 DATED Nov. 11, 1975 INV ENTOR(S) George R. Lenz ltis certified that error appears in the aboveidentified patent and that said Letters Patent are hereby corrected as shown below:

' Column 1, line 47, lactone" should read *r-lactone Column 2, line 26, "C H should read C H Column 2, line 43, "intra-gastrically," should read intragastrically;

Column 2, line 57, "index lO/K." should read index of Column 2, line 62, "of 0:" should read of i Column 2, line 66, "(P 0.05)" should read (P 0.05)

Column 2, line 67, "is us" should read is i Column 2, line 68, "Na 1/ lO/K" should read Na x lO/K Column 3, line 9, "3,5,1?" should read 3B,5or,l7

Column 3, line 9, "acid should read acid Y- Column 3, line 15, "3,5,1?" should read 3B,5or,l7

Column 3, line 15, "17-pregnane" should read lYa-pregnane Column 3, line 16, "-lactone" should read -lac-tone Column 3, line 17, "3-acecyloxy-5,l7" should read 3B-acetyloxy-5or,l7

Column 3, line 9, "l'I-pregnane should read lYOT-pregnane UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION Page 3 f 5 PATENTNO.: 3,919, 99

DATED Nov. 11, 1975 INV ENTOR(S) George R. Lenz it is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

Column 3, line 17, "-17-" should read l7d- Column 3, line 18, "lactone" should read Y-lactone Column 3, line 19, "cyanomethy1=phosphonate" should read cyanomethylphosphonate Column 3, line 21, "3-acetyloxy" should read 3B-acetyloxy Column 3, line 22, "5,l7-dihydroxy-l7-" should read Column 3, line 23, "-lactone" should read Y-lactone Column 1, line 1, "0" should read 0 Column 1, line 2, "cyano=methyl" should read cyanomethyl Column 4, line 3, "0" should read 0 Column 4, line 3, "for hour" should read for 1/2 hour Column 4, line 4, "3-acetyloxy-5,l7" should read Column N line 5, "l'I-pregnane" should read l7or-pregnane Column 4, line 5, 'acld -lactone" should read acid -lactone UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION Page 14 of 5 George R. Lenz It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

1 Column 4, line acetyloxy Column 4, line Column line Column l, line -lactone Column l, line Column line "3-acetyloxy" should read 36 "5,17" should read 50,17

"l7-pregnane" should read l'ld-pregnane "acid lactone" should read acid "236-239." should read 236-239.

"3-acetyloxy" should read 3B-ace'cyloxy Column 4, line 23, "-lactone" should read Y-lactone Column l, line 28, "3,5,l7-trihydroxy-l7" should read 3B,5or,l7-trihydroxy-l7or Column l, Claim 1, "3,5,17-trihydroxy-l7" Y-lactone should read 3B,5or,l7-trihydroxy-l7or Column 4, Claim 1, "acid lactone" should acid -lactone read UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION Page 5 of 5 PATENT NO. 1 3,919, 99

DATED Nov. 11, 1975 INVENTOM5): George R. Lenz nmcmmmdmmmmrwmmsmmemwe4wmmwpmmtmdmmsmdLfimmPmmt are hereby corrected as shown below:

Column 4, Claim 2, "B-Acetyloxy" should read 3B- Acetyloxy Column M, Claim 2, "5,17-dihydroxy-l7" should read 5a,l7-dihydroxy-l7a Column U, Claim 2, "acid lactone" should read acid -lactone Signed and Scaled this Thirty-first Day of August 1976 [SEAL] AIIeSI.

RuTnc.M soN .MARSHALLDANN Alresrmg Officer Commissioner nfParc'ms and Trademarks UNITED STATES PATENT AND TRADEMARK ()FFICE CERTIFICATE OF CORRECTION PATENT NO. 1 3,919,199 DATED November 11, 1975 INVENTOR(S) 1 George R. Lenz it is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below Front page, element [5 4], line 1, "501-17" should read 5c1,l7

Front page, element [E i], line 3, "ACID-y" should read ACID y Front page, element [S -i], line i, IN IIElRl iEDIATES" should read INTERMEDIATE THERETO Column 1, line 1, "3,5-l7-TRIHYDROXY-l7" Should read 3B,5a,l7-TRIHYDROXY17 1 Column 1, line 3, "INTERMEDIATES" should read INTERMEDIATE THERETO Signcd and Scaled this First D3) of February 1977 [SEAL] Arrest.

RUTH C. MASON C. MARSHALL DANN Arresting Officer Commissioner nfPalenrs and Trademarks 

1. 6-CYANONMETHYLENE-3B,5A,17-TRIHYDROXY-17A-PREGNANE21-CARBOXYLIC ACID Y-LACTONE.
 2. 3B-ACETYLOXY-6-CYANOMETHYLENE-5A,17-DIHYDROXY-17APREGNANE-21-CARBOXYLIC ACID Y-LACTONE. 